应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
00460 四环医药
已收盘 05-03 16:09:00
0.610
-0.020
-3.17%
最高
0.650
最低
0.600
成交量
928.90万
今开
0.630
昨收
0.630
日振幅
7.94%
总市值
56.91亿
流通市值
56.91亿
总股本
93.30亿
成交额
573.15万
换手率
0.10%
流通股本
93.30亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股异动 | 四环医药(00460)尾盘涨超10% 达希替尼片已向国家药监局申报上市并获得受理
智通财经 · 05-02 15:28
港股异动 | 四环医药(00460)尾盘涨超10% 达希替尼片已向国家药监局申报上市并获得受理
四环医药(00460)上涨10.53%,报0.63元/股
金融界 · 05-02 15:03
四环医药(00460)上涨10.53%,报0.63元/股
医美概念股走高 四环医药(00460)涨8.77% 国金证券指医美行业仍处于高景气发展阶段
金吾财讯 · 05-02 14:06
医美概念股走高 四环医药(00460)涨8.77% 国金证券指医美行业仍处于高景气发展阶段
四环医药(00460.HK)创新药“达希替尼片”向国家药监局申报上市并获受理
阿斯达克财经 · 05-02 12:06
四环医药(00460.HK)创新药“达希替尼片”向国家药监局申报上市并获受理
四环医药(00460.HK):轩竹生物自主研发1类创新药“达希替尼片”向国家药监局申报上市并获得受理
格隆汇资讯 · 05-02 12:05
四环医药(00460.HK):轩竹生物自主研发1类创新药“达希替尼片”向国家药监局申报上市并获得受理
四环医药盘中异动 大幅上涨5.26%
自选股智能写手 · 05-02 11:07
四环医药盘中异动 大幅上涨5.26%
四环医药04月26日获主力加仓517万元 环比增加894.23%
自选股智能写手 · 04-26
四环医药04月26日获主力加仓517万元 环比增加894.23%
四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格
阿斯达克财经 · 04-25
四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格
四环医药(00460):惠升生物研发的三款门冬胰岛素系列产品在胰岛素专项接续采购中获得拟中选资格
智通财经 · 04-25
四环医药(00460):惠升生物研发的三款门冬胰岛素系列产品在胰岛素专项接续采购中获得拟中选资格
南向资金4月16日净买入四环医药402.60万股 连续5日增持
自选股智能写手 · 04-17
南向资金4月16日净买入四环医药402.60万股 连续5日增持
南向资金4月12日净买入四环医药41.30万股 连续3日增持
自选股智能写手 · 04-15
南向资金4月12日净买入四环医药41.30万股 连续3日增持
四环医药04月12日遭主力抛售235万元 环比增加298.31%
自选股智能写手 · 04-12
四环医药04月12日遭主力抛售235万元 环比增加298.31%
四环医药(00460)出现大手卖出290万股,成交价$0.52,涉资150.8万
阿斯达克财经 · 04-12
四环医药(00460)出现大手卖出290万股,成交价$0.52,涉资150.8万
港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间
智通财经 · 04-10
港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间
四环医药(00460)上涨5.77%,报0.55元/股
金融界 · 04-10
四环医药(00460)上涨5.77%,报0.55元/股
四环医药盘中异动 快速拉升5.77%报0.550港元
自选股智能写手 · 04-10
四环医药盘中异动 快速拉升5.77%报0.550港元
四环医药(00460):医美业绩强势爆发 盈利拐点向上撬动估值逻辑
智通财经 · 04-10
四环医药(00460):医美业绩强势爆发 盈利拐点向上撬动估值逻辑
四环医药(00460)下跌5.45%,报0.52元/股
金融界 · 04-05
四环医药(00460)下跌5.45%,报0.52元/股
四环医药盘中异动 股价大跌5.45%
自选股智能写手 · 04-05
四环医药盘中异动 股价大跌5.45%
南向资金4月3日净买入四环医药571.00万股 连续3日增持
自选股智能写手 · 04-05
南向资金4月3日净买入四环医药571.00万股 连续3日增持
暂无数据
公司概况
公司名称:
四环医药
所属市场:
SEHK
上市日期:
--
主营业务:
四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。
发行价格:
--
{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.61,"timestamp":1714723740025,"preClose":0.63,"halted":0,"volume":9289000,"delay":0,"floatShares":9329999206,"shares":9329999206,"eps":-0.0063113975,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.02,"latestTime":"05-03 16:09:00","open":0.63,"high":0.65,"low":0.6,"amount":5731450,"amplitude":0.079365,"askPrice":0.61,"askSize":1120000,"bidPrice":0.6,"bidSize":2927000,"shortable":3,"etf":0,"ttmEps":-0.006311397524265016,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714959000000},"adr":0,"adjPreClose":0.63,"dividendRate":0.056549,"openAndCloseTimeList":[[1714699800000,1714708800000],[1714712400000,1714723200000]],"volumeRatio":0.580468,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460/tweets","defaultTab":"tweets","newsList":[{"id":"2432644000","title":"港股异动 | 四环医药(00460)尾盘涨超10% 达希替尼片已向国家药监局申报上市并获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2432644000","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432644000?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:28","pubTimestamp":1714634893,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,四环医药尾盘涨超10%,截至发稿,涨10.53%,报0.63港元,成交额1623.29万港元。消息面上,四环医药发布公告,集团旗下非全资附属公司轩竹生物自主研发的抗肿瘤1类创新药“达希替尼片”已向中国国家药品监督管理局申报上市并获得受理。达希替尼片为轩竹生物递交上市申请并获得受理的首个肺癌靶向创新药,如果该产品上市申请获批,将是轩竹生物自主研发的的第3个获批上市的创新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1116878.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432641308","title":"四环医药(00460)上涨10.53%,报0.63元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2432641308","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2432641308?lang=zh_cn&edition=full","pubTime":"2024-05-02 15:03","pubTimestamp":1714633388,"startTime":"0","endTime":"0","summary":"5月2日,四环医药(00460)盘中上涨10.53%,截至15:03,报0.63元/股,成交1498.43万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业,主要业务为生产和销售心脑血管处方药物,自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2023年年报,四环医药营业总收入18.61亿元、净利润-5401.7万元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/02150340509888.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432643125","title":"医美概念股走高 四环医药(00460)涨8.77% 国金证券指医美行业仍处于高景气发展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2432643125","media":"金吾财讯","top":-1,"share":"https://www.laohu8.com/m/news/2432643125?lang=zh_cn&edition=full","pubTime":"2024-05-02 14:06","pubTimestamp":1714630013,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医美概念股走高,四环医药(00460)涨8.77%,复锐医疗科技(01696)涨8.15%,三生制药(01530)涨5.41%,医思健康(02138)涨5.34%,康哲药业(00867)涨4.56%,复星医药(02196)涨2.76%。国金证券表示,看好兼具技术、产品、品牌储备的国内医美龙头。现阶段受到情绪面的影响,国内医美板块估值已经回调至相对低位。展望国内医美行业未来发展,该行认为行业仍处于高景气发展阶段。未来我国医美行业发展有望受益于合规产品占比提升与医美渗透率提升的双重驱动,竞争格局不断优化,新需求持续放量,行业业绩和估值有较大提升空间。","market":"hk","thumbnail":"https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTA2NWNmYzE4MTQyOTUwMjEyNTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1936162","is_publish_highlight":false,"gpt_icon":0},{"id":"2432615039","title":"四环医药(00460.HK)创新药“达希替尼片”向国家药监局申报上市并获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2432615039","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2432615039?lang=zh_cn&edition=full","pubTime":"2024-05-02 12:06","pubTimestamp":1714622760,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布,旗下非全资附属公司轩竹生物自主研发的抗肿瘤1类创新药“达希替尼片”(产品代号:XZP-3621)已向国家药监局申报上市并获得受理。是次申报的适应症具体为适用于间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移性非小细胞肺癌(NSCLC)患者的治疗。达希替尼片为轩竹生物递交上市申请并获得受理的首个肺癌靶向创新药,如果该产品上市申请获批,将是轩竹生物自主研发的的第3个获批上市的创新药。(sl/cy)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-30 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1346866/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432156116","title":"四环医药(00460.HK):轩竹生物自主研发1类创新药“达希替尼片”向国家药监局申报上市并获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2432156116","media":"格隆汇资讯","top":-1,"share":"https://www.laohu8.com/m/news/2432156116?lang=zh_cn&edition=full","pubTime":"2024-05-02 12:05","pubTimestamp":1714622759,"startTime":"0","endTime":"0","summary":"格隆汇5月2日丨四环医药发布公告,集团旗下非全资附属公司轩竹生物科技股份有限公司自主研发的抗肿瘤1类创新药“达希替尼片”已向中国国家药品监督管理局申报上市并获得受理。达希替尼片为新一代ALK抑制剂药物,其独特的结构设计提高了分子对耐药位点的抑制活性。此外,XZP-3621能够穿过血脑屏障,对肿瘤脑转移有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021206048b6bd5f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021206048b6bd5f2&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2432469756","title":"四环医药盘中异动 大幅上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432469756","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2432469756?lang=zh_cn&edition=full","pubTime":"2024-05-02 11:07","pubTimestamp":1714619279,"startTime":"0","endTime":"0","summary":"2024年05月02日早盘11时07分,四环医药股票出现异动,股价急速上涨5.26%。截至发稿,该股报0.600港元/股,成交量1118.4万股,换手率0.12%,振幅7.02%。机构评级方面,目前暂无机构对该股做出“买入、持有、卖出”建议。四环医药股票所在的药品行业中,整体涨幅为0.44%。其相关个股中,君圣泰医药-B、培力农本方、长江生命科技涨幅较大,振幅较大的相关个股有君圣泰医药-B、康龙化成、开拓药业-B,振幅分别为12.96%、8.24%、7.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021107597a57e5c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405021107597a57e5c3&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430550241","title":"四环医药04月26日获主力加仓517万元 环比增加894.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430550241","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2430550241?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:16","pubTimestamp":1714119389,"startTime":"0","endTime":"0","summary":"04月26日, 四环医药股价涨3.70%,报收0.56元,成交金额880万元,换手率0.17%,振幅5.56%,量比2.61。四环医药今日主力资金净流入517万元,连续3日净流入,上一交易日主力净流入52万元,今日环比增加894.23%。近一年数据显示,该股主力连续3日净流入后,次日上涨概率为35.71%,平均涨幅为3.32%。该股近5个交易日上涨7.84%,主力资金累计净流入713万元;近20日主力资金累计净流入148万元,其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616173187b2a22f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042616173187b2a22f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430479846","title":"四环医药(00460.HK)三款门冬胰岛素系列产品在专项接续采购中获得拟中选资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2430479846","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2430479846?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:26","pubTimestamp":1714037160,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布,4月23日,旗下非全资附属公司惠升生物参加了联合采购办公室组织的全国药品集中采购(胰岛素专项接续)的申报工作。惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在是次胰岛素专项接续采购中获得拟中选资格,且均拟中选A类品种。是次胰岛素集中采购周期自中选结果执行之日起至2027年12月31日。(sl/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-04-25 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154450154_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/analysis/china-hot-topic-content.aspx?id=NOW.1345132&catg=4&source=AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2430476934","title":"四环医药(00460):惠升生物研发的三款门冬胰岛素系列产品在胰岛素专项接续采购中获得拟中选资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2430476934","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430476934?lang=zh_cn&edition=full","pubTime":"2024-04-25 17:20","pubTimestamp":1714036842,"startTime":"0","endTime":"0","summary":"惠升生物研发的门冬胰岛素注射液及门冬胰岛素30注射液、门冬胰岛素50注射液三款产品在本次胰岛素专项接续采购中获得拟中选资格,且均拟中选A类品种。本次胰岛素集中采购周期自中选结果执行之日起至 2027年 12月31日。同时,将进一步提升胰岛素产品可及性,惠及国内广大患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109926.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428733489","title":"南向资金4月16日净买入四环医药402.60万股 连续5日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2428733489","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428733489?lang=zh_cn&edition=full","pubTime":"2024-04-17 09:31","pubTimestamp":1713317473,"startTime":"0","endTime":"0","summary":"4月16日, 南向资金增持四环医药402.60万股,连续5日增持。截止当日收盘,港股通共持有四环医药86686.50万股,占流通股9.28%。四环医药近5个交易日下跌3.85%,港股通累计增持948.00万股;近20个交易日下跌15.25%,港股通累计增持1699.70万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170947398b2cb14a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404170947398b2cb14a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427609420","title":"南向资金4月12日净买入四环医药41.30万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2427609420","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427609420?lang=zh_cn&edition=full","pubTime":"2024-04-15 09:31","pubTimestamp":1713144669,"startTime":"0","endTime":"0","summary":"4月12日, 南向资金增持四环医药41.30万股,连续3日增持。截止当日收盘,港股通共持有四环医药86227.70万股,占流通股9.24%。港股通增持金额前五个股分别为中国石油股份、中国移动、中国银行、兖矿能源、中通快递-W。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404150944308b23b5f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404150944308b23b5f8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426270910","title":"四环医药04月12日遭主力抛售235万元 环比增加298.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426270910","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426270910?lang=zh_cn&edition=full","pubTime":"2024-04-12 16:16","pubTimestamp":1712909763,"startTime":"0","endTime":"0","summary":"04月12日, 四环医药股价跌3.70%,报收0.52元,成交金额651万元,换手率0.13%,振幅3.70%,量比1.18。四环医药今日主力资金净流出235万元,上一交易日主力净流出59万元,今日环比增加298.31%。该股主力净额占比0.05%,港股市场排名2532/2628。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412161657876d9ebd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412161657876d9ebd&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426277564","title":"四环医药(00460)出现大手卖出290万股,成交价$0.52,涉资150.8万","url":"https://stock-news.laohu8.com/highlight/detail?id=2426277564","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2426277564?lang=zh_cn&edition=full","pubTime":"2024-04-12 15:55","pubTimestamp":1712908500,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:55出现大手卖出,成交量为290万,成交价为港币$0.52,涉资150.8万。至目前为止,股价跌3.704%,今日最高价为$0.54,而最低价为$0.52,总成交量为1.077千万股,总成交金额港币$569.408万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180815142908927_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2404123307/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2426101000","title":"港股异动 | 四环医药(00460)涨超5% 23年公司医美收益大幅增长 机构认为我国医美渗透率仍有较大提升空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2426101000","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426101000?lang=zh_cn&edition=full","pubTime":"2024-04-10 10:15","pubTimestamp":1712715302,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,四环医药涨超5%,截止发稿涨5.77%,报0.55港元,成交额294万港元。华泰证券表示,23年医美行业新品获批阶段性空窗期,叠加需求较弱,倒逼下游机构“以价换量”,同质化较强/成熟度较高/价格带透明的产品易陷入低价引流困境,预计24年新品获批数量相较23年增加,对于终端需求有提振作用。中长期来看,我国医美渗透率仍有较大提升空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100407.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426104937","title":"四环医药(00460)上涨5.77%,报0.55元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426104937","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426104937?lang=zh_cn&edition=full","pubTime":"2024-04-10 10:02","pubTimestamp":1712714573,"startTime":"0","endTime":"0","summary":"4月10日,四环医药(00460)盘中上涨5.77%,截至10:02,报0.55元/股,成交284.52万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业,主要业务为生产和销售心脑血管处方药物,自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2023年年报,四环医药营业总收入18.61亿元、净利润-5401.7万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/10100240176383.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2426101173","title":"四环医药盘中异动 快速拉升5.77%报0.550港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2426101173","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426101173?lang=zh_cn&edition=full","pubTime":"2024-04-10 10:02","pubTimestamp":1712714568,"startTime":"0","endTime":"0","summary":"2024年04月10日早盘10时02分,四环医药股票出现波动,股价急速上涨5.77%。截至发稿,该股报0.550港元/股,成交量528.3万股,换手率0.06%,振幅5.77%。资金方面,该股资金流入255.584万港元,流出14.726万港元。四环医药股票所在的药品行业中,整体跌幅为0.09%。其相关个股中,四环医药、中生联合、东阳光长江药业涨幅较大,振幅较大的相关个股有三爱健康集团、中生联合、联康生物科技集团,振幅分别为17.65%、14.04%、8.60%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101002497a51c25d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404101002497a51c25d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426108946","title":"四环医药(00460):医美业绩强势爆发 盈利拐点向上撬动估值逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2426108946","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2426108946?lang=zh_cn&edition=full","pubTime":"2024-04-10 09:15","pubTimestamp":1712711750,"startTime":"0","endTime":"0","summary":"根据国内报告,2022年中国医美手术收入占比48%,非手术收入占比52%。在生产端,四环医药产品覆盖轻医美的基础类别,落成两个生产基地及7条生产线,确保部分产品获批后能快速实现产业化发展。随着产品储备丰富,四环医药医美板块有望持续加码高景气赛道,业绩增长有望延续。就行业贝塔来看,四环医药将享受医美+医药行业增长红利。随着医美平台化价值释放,四环医药将持续攫取轻医美市场的规模红利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1100373.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425304032","title":"四环医药(00460)下跌5.45%,报0.52元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425304032","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425304032?lang=zh_cn&edition=full","pubTime":"2024-04-05 11:39","pubTimestamp":1712288354,"startTime":"0","endTime":"0","summary":"4月5日,四环医药(00460)盘中下跌5.45%,截至11:39,报0.52元/股,成交106.36万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业,主要业务为生产和销售心脑血管处方药物,自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2023年年报,四环医药营业总收入18.61亿元、净利润-5401.7万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/05113940129265.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425022309","title":"四环医药盘中异动 股价大跌5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2425022309","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425022309?lang=zh_cn&edition=full","pubTime":"2024-04-05 11:05","pubTimestamp":1712286333,"startTime":"0","endTime":"0","summary":"2024年04月05日早盘11时05分,四环医药股票出现异动,股价急速跳水5.45%。截至发稿,该股报0.520港元/股,成交量152.2万股,换手率0.02%,振幅3.64%。资金方面,该股资金流入16.71万港元,流出64.103万港元。四环医药股票所在的药品行业中,整体跌幅为0.22%。其相关个股中,前海健康、三爱健康集团、天大药业涨幅较大,振幅较大的相关个股有三爱健康集团、康龙化成、复星医药,振幅分别为16.22%、9.71%、8.85%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405110533791ed43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405110533791ed43d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425377477","title":"南向资金4月3日净买入四环医药571.00万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2425377477","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425377477?lang=zh_cn&edition=full","pubTime":"2024-04-05 09:30","pubTimestamp":1712280616,"startTime":"0","endTime":"0","summary":"4月3日, 南向资金增持四环医药571.00万股,连续3日增持。截止当日收盘,港股通共持有四环医药85602.40万股,占流通股9.17%。四环医药近5个交易日下跌1.79%,港股通累计增持757.00万股;近20个交易日下跌3.51%,港股通累计增持1350.40万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040509304287e0053b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040509304287e0053b&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.1667},{"period":"1month","weight":0.1667},{"period":"3month","weight":0.2353},{"period":"6month","weight":-0.0597},{"period":"1year","weight":-0.1818},{"period":"ytd","weight":-0.0308}],"compareEarnings":[{"period":"1week","weight":0.0534},{"period":"1month","weight":0.0753},{"period":"3month","weight":0.1721},{"period":"6month","weight":0.0307},{"period":"1year","weight":-0.0757},{"period":"ytd","weight":0.068}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.124332},{"month":2,"riseRate":0.571429,"avgChangeRate":0.002088},{"month":3,"riseRate":0.357143,"avgChangeRate":-0.025475},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029528},{"month":5,"riseRate":0.461538,"avgChangeRate":0.006541},{"month":6,"riseRate":0.583333,"avgChangeRate":-0.004012},{"month":7,"riseRate":0.5,"avgChangeRate":-0.008059},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.027927},{"month":9,"riseRate":0.083333,"avgChangeRate":-0.082523},{"month":10,"riseRate":0.583333,"avgChangeRate":0.030986},{"month":11,"riseRate":0.538462,"avgChangeRate":0.020616},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.01024}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}